CSF1R and ischemia: In the present study, our results indicated that the Ki20227, as CSF1R inhibitor administration, could improve ischemia-induced behavioral deficits of mice and attenuate microglia-related inflammation, which is validated by the downregulation of mRNA expression in both microglia M1 phenotype factors and Iba1 protein expression, meanwhile, increase of microglia M2 phenotype expression shown as in Figure 7.